Description: Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Home Page: www.liquidia.com
419 Davis Drive
Morrisville,
NC
27560
United States
Phone:
919 328 4400
Officers
| Name | Title |
|---|---|
| Dr. Roger A. Jeffs Ph.D. | CEO & Director |
| Mr. Michael Kaseta | COO & CFO |
| Mr. Russell Schundler | General Counsel & Corporate Secretary |
| Mr. William R. Kenan Jr. | Co-Founder |
| Dr. Ginger Denison | Co-Founder |
| Ms. Sarah Krepp SPHR | Vice President of People & Culture |
| Mr. Jason Adair | Chief Business Officer |
| Mr. Scott Moomaw | Chief Commercial Officer |
| Dr. Rajeev Saggar M.D. | Chief Medical Officer |
| Mr. Michael Hunter | Senior Vice President of Manufacturing Operations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.7144 |
| Price-to-Sales TTM: | 62.2844 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 145 |